Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta

Reuters
2025.12.03 12:32
Dec 3 (Reuters) - ADC Therapeutics SA (ADCT.N) : * ADC THERAPEUTICS ANNOUNCES UPDATED DATA FROM LOTIS-7 PHASE 1B CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH BISPECIFIC ANTIBODY SUPPORTING POTENTIAL BEST-IN-CLASS REGIMEN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA * ADC THERAPEUTICS SA - LOTIS-7 TRIAL ON TRACK FOR COMPLETE ENROLLMENT IN 1H 2026 Source text: Further company coverage: (ADCT.N)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer